	US 11,891,450 B2
	Anti-CD47 agent-based treatment of CD20-positive cancer
Mark Ping Chao, Mountain View, CA (US); Chris Hidemi Mizufune Takimoto, Menlo Park, CA (US); and Jens-Peter Volkmer, Menlo Park, CA (US)
Assigned to Forty Seven, Inc., Foster City, CA (US)
Filed by Forty Seven, Inc., Foster City, CA (US)
Filed on Feb. 11, 2019, as Appl. No. 16/272,350.
Claims priority of provisional application 62/743,875, filed on Oct. 10, 2018.
Claims priority of provisional application 62/743,060, filed on Oct. 9, 2018.
Claims priority of provisional application 62/678,468, filed on May 31, 2018.
Claims priority of provisional application 62/629,340, filed on Feb. 12, 2018.
Prior Publication US 2019/0248915 A1, Aug. 15, 2019
Int. Cl. C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61P 35/00 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/30 (2013.01) [A61K 39/39558 (2013.01); A61P 35/00 (2018.01); C07K 16/2803 (2013.01); C07K 16/2887 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55 (2013.01); A61K 2039/804 (2018.08); C07K 2317/24 (2013.01); C07K 2317/732 (2013.01)]

20 Claims

1. A method of effectively treating or reducing cancer burden with an overall response rate of at least 40% in human subjects, wherein the human subjects have Non-Hodgkin's lymphoma (NHL) and are refractory to rituximab, comprising:

(a) determining, before administering steps, that the human subjects are refractory to rituximab;

(b) selecting the refractory subjects for treatment;

(c) administering to the refractory subjects for four weeks a first cycle comprising (1) a priming dose of anti-CD47 antibody at about 1 mg of antibody per kg of body weight at time 0 (T0), (2) a dose of at least 30 mg of the anti-CD47 antibody per kg of body weight once every week beginning one week after TO, and (3) a dose of 375 mg/m²of anti-CD20 antibody once every week; and

(d) administering to the refractory subjects for four weeks a second cycle comprising (1) a dose of at least 30 mg of the anti-CD47 antibody per kg of body weight once every two weeks, and (2) a dose of 375 mg/m²of the anti-CD20 antibody once every four weeks;

thereby effectively treating or reducing cancer burden in the refractory subjects such that an overall response rate (ORR) of at least 40% is achieved.